Subscribe To
MORF / Morphic Holding, Inc. (MORF) Reports Q2 Loss, Lags Revenue Estimates
MORF News
By Seeking Alpha
September 28, 2023
Morphic Holding: The Price Drop Is Very Interesting
Morphic Holding, Inc.'s stock has dropped 61% in just 2 months, calling into question its $3bn valuation. The company's lead asset, MORF-057, targets more_horizontal
By GlobeNewsWire
September 22, 2023
Morphic to Present Positive EMERALD-1 Phase 2a Data for MORF-057 in Patients with Moderate to Severe Ulcerative Colitis in Abstract for UEGW 2023
-Orally administered MORF-057 achieved primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures- more_horizontal
By Zacks Investment Research
August 3, 2023
Morphic Holding, Inc. (MORF) Reports Q2 Loss, Lags Revenue Estimates
Morphic Holding, Inc. (MORF) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares t more_horizontal
By Seeking Alpha
July 10, 2023
Morphic: High Valuation Not Justified By Data, Development Status, Or Cash
Morphic Holding, Inc. is progressing with its trials nicely enough. I just have a problem with the nearly $3bn valuation for this phase 2 stage compan more_horizontal
By The Motley Fool
April 29, 2023
3 Biotech Buyout Targets to Watch
89bio's stock is up more than 21% this year. Karuna Therapeutics says it plans to file an NDA for its lead therapy this year. more_horizontal
By Seeking Alpha
April 25, 2023
Morphic: Positive Phase 2a UC Trial, Top M&A Candidate In 2023
Morphic: Positive Phase 2a UC Trial, Top M&A Candidate In 2023. more_horizontal
By Zacks Investment Research
April 25, 2023
Morphic Holding, Inc. (MORF) Reports Q1 Loss, Lags Revenue Estimates
Morphic Holding, Inc. (MORF) came out with a quarterly loss of $0.90 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares t more_horizontal
By Zacks Investment Research
April 18, 2023
Morphic Holding, Inc. (MORF) Moves 22.5% Higher: Will This Strength Last?
Morphic Holding, Inc. (MORF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings esti more_horizontal